Susan D. Wyrick - Oct 4, 2024 Form 3 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney
Signature
/s/ Julie Shah, Attorney-in-Fact for Susan D. Wyrick
Stock symbol
SANA
Transactions as of
Oct 4, 2024
Transactions value $
$0
Form type
3
Date filed
10/15/2024, 06:43 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SANA Common Stock 148K Oct 4, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SANA Stock Option (Right to buy) Oct 4, 2024 Common Stock 65K $7.80 Direct F1
holding SANA Stock Option (Right to buy) Oct 4, 2024 Common Stock 63K $5.70 Direct F2
holding SANA Stock Option (Right to buy) Oct 4, 2024 Common Stock 36.6K $3.76 Direct F3
holding SANA Stock Option (Right to buy) Oct 4, 2024 Common Stock 58.5K $9.58 Direct F4
holding SANA Restricted Stock Units Oct 4, 2024 Common Stock 4.58K Direct F5, F6
holding SANA Restricted Stock Units Oct 4, 2024 Common Stock 12.5K Direct F5, F7
holding SANA Restricted Stock Units Oct 4, 2024 Common Stock 13K Direct F5, F8
holding SANA Restricted Stock Units Oct 4, 2024 Common Stock 20K Direct F5, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the shares underlying the option on February 15, 2022 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. ("Sana") as an employee, consultant, director or officer of Sana through each such date.
F2 The option vested as to 25% of the shares underlying the option on March 3, 2023 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3 The option vested as to 25% of the shares underlying the option on March 2, 2024 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F4 The option vests as to 25% of the shares underlying the option on March 7, 2025 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F5 Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
F6 The award vested as to 25% of the restricted stock units on March 2, 2024 and the remainder vests in equal installments on each of March 2, 2025, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F7 The award vests as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F8 The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F9 The restricted stock units vest in two equal installments on each of June 3, 2025 and December 3, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date; provided, that if Sana terminates the reporting person's employment without cause, subject to her execution of a release of claims, then any outstanding restricted stock units that have not vested on or prior to the reporting person's termination date shall vest immediately upon such termination date.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney